Summary
The AI response does not accurately evaluate against the supplied FDA label text; it concludes unsupported due to unverifiable placeholder section numbering, despite the provided label excerpt clearly stating NSAIDs including ELYXYB are contraindicated in CABG.
Category Scores
Accurate Statements
Unsupported Statements
Contradictions
High
AI Statement
The claim that ELYXYB is contraindicated in the setting of CABG surgery is unsupported by the FDA label.
Label Reference
Contraindications 4 (CABG surgery): "In the setting of coronary artery bypass graft (CABG) surgery" and Warnings and Precautions 5.1 (within 5.1): "NSAIDs, including ELYXYB, are contraindicated in the setting of CABG".
Important Omissions
The response failed to cite/quote the provided label excerpt lines that explicitly state NSAIDs including ELYXYB are contraindicated in CABG and that ELYXYB is contraindicated in CABG surgery.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Incorrectly labeling a CABG contraindication as unsupported could lead to inaccurate safety handling.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
The evaluation decision is incorrect: the provided label text explicitly states CABG is a contraindication for NSAIDs including ELYXYB.
Suggested Improvement
When the label excerpt includes explicit contraindication language ("NSAIDs, including ELYXYB, are contraindicated in the setting of CABG" and/or the Contraindications list), mark the claim as supported and cite the provided excerpt verbatim rather than rejecting due to unverified section numbering placeholders.